1875 — BioDlink International Co Share Price
0.000.00%
Last trade - 00:00- HK$3.86bn
- HK$3.93bn
- CNY747.65m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.42 | ||
| Price to Tang. Book | 5.52 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.54 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.2% | ||
| Return on Equity | -14.81% | ||
| Operating Margin | -12.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 76.33 | 442.18 | 780.63 | 1,098.33 | 747.64 | 1,509.15 | n/a | 101.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioDlink International Co Ltd, formerly TOT BIOPHARM International Co Ltd, is a clinical-stage biopharmaceutical company principally engaged in developing and commercializing oncology drugs and therapies. The Company and its subsidiaries are primarily engaged in research, development, manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO) business and license-out of self-developed biological drugs in the People’s Republic of China. The Company owns a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The Company has built and established a fully integrated in-house platform of discovery, process development, quality management, pre-clinical and clinical development, as well as commercial-scale manufacturing facilities and sales and marketing capabilities. The Company mainly conducts its businesses in the domestic market.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- December 4th, 2009
- Public Since
- November 8th, 2019
- No. of Employees
- 604
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 772,787,887
- Address
- 120 Changyang Street, Suzhou, 215024
- Web
- https://www.biodlink.com/
- Phone
- +86 51262965186
- Contact
- Yan Chen
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 1875
Half Year 2026 BioDlink International Co Ltd Earnings Release
Similar to 1875
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the BioDlink International Co share price?
As of Today at 10:35 UTC, shares in BioDlink International Co are trading at HK$5.00. This share price information is delayed by 15 minutes.
How has the BioDlink International Co share price performed this year?
Shares in BioDlink International Co last closed at HK$5.00 and the price had moved by +142.72% over the past 365 days. In terms of relative price strength the BioDlink International Co share price has outperformed the FTSE Developed Asia Pacific Index by +57.85% over the past year.
What are the analyst and broker recommendations for BioDlink International Co?
The overall consensus recommendation for BioDlink International Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioDlink International Co dividend yield?
BioDlink International Co does not currently pay a dividend.
Does BioDlink International Co pay a dividend?
BioDlink International Co does not currently pay a dividend.
When does BioDlink International Co next pay dividends?
BioDlink International Co does not currently pay a dividend.
How do I buy BioDlink International Co shares?
To buy shares in BioDlink International Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioDlink International Co?
As of the previous close price of HK$5.00, shares in BioDlink International Co had a market capitalisation of HK$3.86bn.
Where are BioDlink International Co shares listed?
Here are the trading details for BioDlink International Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1875
What kind of share is BioDlink International Co?
Based on an overall assessment of its quality, value and momentum BioDlink International Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioDlink International Co share price forecast for 2026?
The analyst consensus target price for shares in BioDlink International Co is HK$2.40. That is 52% below the last closing price of HK$5.00.
Analysts covering BioDlink International Co currently have a consensus Earnings Per Share (EPS) forecast of CNY0.17 for the next financial year.
Find out moreWhat is the trend in the BioDlink International Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioDlink International Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +82.82%.
As of the last closing price of HK$5.00, shares in BioDlink International Co were trading +82.88% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioDlink International Co PE Ratio?
The BioDlink International Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$5.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioDlink International Co?
We do not have data on BioDlink International Co's directors